RecruitingPhase 3NCT05275972

Descemet Endothelial Thickness Comparison Trial II

Studying Corneal dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Stanford University
Principal Investigator
Jennifer Rose-Nussbaumer, MD
Stanford University
Intervention
Ripasudil(drug)
Enrollment
60 enrolled
Eligibility
18 years · All sexes
Timeline
20232028

Study locations (7)

Collaborators

Oregon Health and Science University · University of California, San Francisco · University of California, Davis · Case Western Reserve University · Dartmouth-Hitchcock Medical Center · University of Pennsylvania · University of Miami · Wills Eye Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05275972 on ClinicalTrials.gov

Other trials for Corneal dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Corneal dystrophy

← Back to all trials